Moneycontrol PRO
Upcoming Event : LeapToUnicorn - mentoring, networking and fundraising for startups. Register now

Hold Zydus Lifesciences; target of Rs 480: ICICI Direct

ICICI Direct recommended hold rating on Zydus Lifesciences with a target price of Rs 480 in its research report dated November 14, 2022.

November 23, 2022 / 02:50 PM IST
  • bselive
  • nselive
Todays L/H

ICICI Direct's research report on Zydus Lifesciences

Zydus is a leading pharma company with family pedigree having a presence in domestic branded formulations, US generics and is in the process of repurposing itself into niche areas of specialty pharmaceuticals, biosimilars and vaccines. FY22 revenue break-up – US: 39%, India: 32%, Wellness: 13%, Europe & emerging markets including countries in LatAm, Asia Pacific & Africa: 10% • Zydus is the fourth largest pharma company in India with 14 brands among Top 300 pharma brands in India and nine with Rs 100 crore+ sales.


We maintain HOLD rating as we wait for 1) consistency from US business in terms of continued traction in base business and new launches momentum (post Moraiya EIR) and 2) continuum in Wellness and India formulations. We value Zydus Lifesciences at Rs 480 (base business of Rs 455 at 18x P/E on FY24E EPS of Rs 25.3 + NPV of Rs 23.5 for gRevlimid opportunity).

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Zydus Lifesciences - 14 -11-2022 - icici

Broker Research
first published: Nov 23, 2022 02:50 pm